Bristol-Myers Squibb (BMS) has entered an agreement with the Netherlands-based molecular diagnostics developer Qiagen for the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs).

The firms plan to utilise the GEPs as predictive or prognostic tools with BMS’ new immuno-oncology (I-O) therapies for the treatment of cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The partnership will leverage BMS’ I-O therapies in combination with Qiagen’s NGS technologies, and its expertise in development and commercialisation of companion and complementary diagnostics.

BMS Oncology development head Fouad Namouni said: “Greater precision in the treatment of cancer may enable faster decision-making to identify which patient populations are most likely to derive benefit from our immuno-oncology agents.

"We believe working with Qiagen will help develop better diagnostic tools to target the most appropriate immunotherapies across a number of different tumour types."

“We believe working with Qiagen will help develop better diagnostic tools to target the most appropriate immunotherapies across a number of different tumour types.”

See Also:

Initially, the firms intend to develop GEPs for various BMS I-O molecules, with plans for a further agreement to use the GEPs for developing new diagnostic products, as well as to extend the use of NGS technology for other BMS I-O therapies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Qiagen CEO Peer Schatz said: “Our teams at QIAGEN are looking forward to working with Bristol-Myers Squibb to leverage the power of NGS technology to potentially improve outcomes for patients.”

BMS and Qiagen have been collaborating since 2009, while their Therascreen KRAS companion/complementary diagnostic assay secured approval from the US Food and Drug Administration (FDA) in 2012.